Faculty

Institution

Unit

Venue

Hun Ju Lee

Assistant Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Lymphoma And Myeloma

Hun Ju Lee is an Assistant Professor at The University of Texas MD Anderson Cancer Center. His research focuses on hematological malignancies, specifically Hodgkin lymphoma and follicular lymphoma, with an emphasis on novel immunotherapeutic combinations, including brentuximab vedotin and nivolumab, and circulating tumor DNA assessment. His recent work has demonstrated the efficacy of nivolumab plus ifosfamide, carboplatin, and etoposide as a first salvage regimen for high-risk relapsed/refractory Hodgkin lymphoma. He has also investigated immune-mediated diseases post-transplantation and prognostic factors for mortality in cancer patients with COVID-19.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Hun Ju Lee

The University of Texas MD Anderson Cancer Center

Assistant Professor

You can click a keyword to filter the displayed items

oncology medicine hematology lymphoid neoplasia immunology pharmacology cancer immunotherapy cancer treatment cancer research hematological malignancies immunotherapy medicinal research cancer care radiation oncology cellular therapy pharmacotherapy leukemia clinical research laboratory medicine anti-cancer agents hepatology clinical transplantation cell therapy clinical immunology clinical trials mantle cell lymphoma large b-cell lymphoma brentuximab vedotin experimental medicine cancer biology cancer management cancer genomics immunohaematology radiation therapy hemostasis cancer genetics surgical oncology thrombosis cell transplantation bone marrow transplantation therapeutic efficacy transplantation medicine drug targeting axicabtagene ciloleucel phase ii study jama oncology malignant blood disorders clinical mycology hodgkin lymphoma chronic lymphocytic leukemia metabolic syndrome clinical radiation oncology lymphatic disease positron emission tomography medical mycology myeloid neoplasia anticoagulants disease progression disease risk assessment tumor suppressors frontline treatment laparoscopy robot-assisted surgery benchmark studies geriatric medicine survival outcome clinical microbiology single-cell analysis cytokines refractory hodgkin lymphoma prognostic impact immune reconstitution hematopoietic recovery hematologic malignancies first-line therapy elderly patients

Notable Scholarly Works

Notable Federal Grants

Collaborators

Post-Pandemic Structural Shifts in Perinatal Characteristics and Outcomes. Journal of Perinatal Medicine (2026)

pediatricsreproductive healthhigh-risk pregnanciesmaternal healthhealth sciencesobstetrics and gynaecology

Risk of Selected Immune-Mediated Diseases After Solid Organ Transplantation in a Korean Nationwide Cohort. Mendeley Data (2026)

epidemiologysolid organ transplantationorgan transplantationimmunologyclinical epidemiologymedicineautoimmune diseasesclinical transplantationgraft survivalliver transplantation

A Phase 2 Study of Obinutuzumab Combined With Lenalidomide in Previously Untreated High Tumor Burden Follicular Lymphoma. Blood Advances (2025)

pathologylymphoid neoplasiaimmunologyhematological malignancieshematologyphase 2gynecologyovarian cancerleukemiaoncology

A Phase II, Single-Center, Single-Arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Ptcl (Golden Study). Blood (2025)

golden studyclinical therapeuticsmetronomic chemotherapyclinical investigationphase iimedicinepharmacologysingle-arm studyclinical researchpharmacotherapyclinical trialsoncology

Brentuximab Vedotin and Nivolumab for Untreated Patients With Hodgkin Lymphoma: Long-Term Results. Blood Advances (2025)

pathologyradiation oncologybrentuximab vedotincancer immunotherapyuntreated patientsjama oncologymedicinethoracic oncologycancer treatmentlymphoid neoplasiahodgkin lymphomaoncology

Circulating Tumor Dna Assessment in Patients With Early-Stage Classical Hodgkin Lymphoma Treated With Combination of Brentuximab Vedotin and Nivolumab.. Journal of Clinical Oncology (2025)

hematological malignancieshematologymolecular diagnosticsmedicinebiomarkerslymphoid neoplasiaoncology

Consolidation With Loncastuximab Tesirine for Large B-Cell Lymphoma Patients in Partial Response After Cart: Planned Interim Futility Analysis of a Phase II Trial. Blood (2025)

radiation oncologypartial responseinterim futility analysisloncastuximab tesirinesurgical oncologyhematological malignancieshematologyimmunotherapyjama oncologymedicinelymphoid neoplasiaclinical trialsoncology

Durable Responses in the Updated 2-Year Follow-Up of Patients From a Single-Center With Relapsed/Refractory Peripheral T-Cell Lymphoma Treated With Golidocitinib. Blood (2025)

cell therapylymphoid neoplasiaupdated 2-year follow-upimmunologyhematological malignanciesimmunotherapyhematologybone marrow transplantationadult t-cell leukemia-lymphomadurable responsesmedicineleukemiaoncology

Germline Variants and Their Role in the Pathogenesis of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (Iec-Hs) in Adult Lymphoma Patients. Blood (2025)

germline variantspathologylymphoid neoplasiaadult lymphoma patientsimmunologyhematologyadult t-cell leukemia-lymphomaimmune responsesleukemia

How Allergic Conditions Influence Hygiene Practices Among Adolescents: Insights From a Nationwide Youth Survey Data. International Journal of Environmental Health Research (2025)

public healthpediatricsenvironmental exposuresadolescent healthpediatric pulmonologyenvironmental healthenvironmental allergiesallergyallergy preventionindoor air qualitypediatric allergy

1
2
3
4
5
27
10 / page

Hun Ju Lee

Assistant Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Lymphoma And Myeloma

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Hun Ju Lee

The University of Texas MD Anderson Cancer Center

Assistant Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Post-Pandemic Structural Shifts in Perinatal Characteristics and Outcomes. Journal of Perinatal Medicine (2026)

pediatricsreproductive healthhigh-risk pregnanciesmaternal healthhealth sciencesobstetrics and gynaecology

Risk of Selected Immune-Mediated Diseases After Solid Organ Transplantation in a Korean Nationwide Cohort. Mendeley Data (2026)

epidemiologysolid organ transplantationorgan transplantationimmunologyclinical epidemiologymedicineautoimmune diseasesclinical transplantationgraft survivalliver transplantation

A Phase 2 Study of Obinutuzumab Combined With Lenalidomide in Previously Untreated High Tumor Burden Follicular Lymphoma. Blood Advances (2025)

pathologylymphoid neoplasiaimmunologyhematological malignancieshematologyphase 2gynecologyovarian cancerleukemiaoncology

A Phase II, Single-Center, Single-Arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Ptcl (Golden Study). Blood (2025)

golden studyclinical therapeuticsmetronomic chemotherapyclinical investigationphase iimedicinepharmacologysingle-arm studyclinical researchpharmacotherapyclinical trialsoncology

Brentuximab Vedotin and Nivolumab for Untreated Patients With Hodgkin Lymphoma: Long-Term Results. Blood Advances (2025)

pathologyradiation oncologybrentuximab vedotincancer immunotherapyuntreated patientsjama oncologymedicinethoracic oncologycancer treatmentlymphoid neoplasiahodgkin lymphomaoncology

Circulating Tumor Dna Assessment in Patients With Early-Stage Classical Hodgkin Lymphoma Treated With Combination of Brentuximab Vedotin and Nivolumab.. Journal of Clinical Oncology (2025)

hematological malignancieshematologymolecular diagnosticsmedicinebiomarkerslymphoid neoplasiaoncology

Consolidation With Loncastuximab Tesirine for Large B-Cell Lymphoma Patients in Partial Response After Cart: Planned Interim Futility Analysis of a Phase II Trial. Blood (2025)

Durable Responses in the Updated 2-Year Follow-Up of Patients From a Single-Center With Relapsed/Refractory Peripheral T-Cell Lymphoma Treated With Golidocitinib. Blood (2025)

Germline Variants and Their Role in the Pathogenesis of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (Iec-Hs) in Adult Lymphoma Patients. Blood (2025)

germline variantspathologylymphoid neoplasiaadult lymphoma patientsimmunologyhematologyadult t-cell leukemia-lymphomaimmune responsesleukemia

How Allergic Conditions Influence Hygiene Practices Among Adolescents: Insights From a Nationwide Youth Survey Data. International Journal of Environmental Health Research (2025)

public healthpediatricsenvironmental exposuresadolescent healthpediatric pulmonologyenvironmental healthenvironmental allergiesallergyallergy preventionindoor air qualitypediatric allergy

1
2
3
4
5
27
10 / page